Esthesioneuroblastoma: Experience at the national institute of neurology and neurosurgery

Abstract

IntroductionEsthesioneuroblastoma or olfactory neuroblastoma (ENB) is a neuroectodermic malignant tumor derived from the olfactory epithelium of the nasal cavity and paranasal sinuses mucosa. It can extend to the superior third of the nasal septum, anterior floor, and intracranial compartment. This article presents the institutional experience and the prognosis of patients with the diagnosis of esthesioneuroblastoma. Patient and MethodsA retrospective study that includes 24 patients with esthesioneuroblastoma. Treatment was based on surgery with later radiotherapy and/or chemotherapy in a period comprehended between October 2009 and September 2019 at our institute. Overall survival (OS) was compared with Kaplan-Meier plots and Log Rank test depending on the treatment, histologic grade, and staging. Results23 patients were included. Just one was excluded because of incomplete records. Mean age was 51.1 ± 14.3, 11 men (47.8%), 12 were female (52.2%). The most common initial symptom was a nasal obstruction in 8 patients, followed by epistaxis and rhinorrhea in 5 patients (21.7%). Ten patients had low-grade esthesioneuroblastoma (LGENB) (43.4%) and 13 high-grade esthesioneuroblastoma (HGENB) (56.5%). The mean accumulated OS was of 86.4 months. ConclusionENB is an infrequent malignant pathology with highly nonspecific symptomatology that delays diagnosis, usually achieved with advanced neuroimaging. Treatment is still controversial. Following international publications, total gross resection is beneficial. It is necessary to perform prospective analyses to establish the best standard of care for this entity.